Combination regimens involving PD-1/PD-L1 inhibitors and CTLA-4 inhibitors have demonstrated superior clinical efficacy compared to monotherapy in multiple randomized trials—including POSEIDON, CheckMate 227, and CheckMate 032—regardless of tumor histology or PD-L1 expression levels (17–19). This evidence concerns the gene CTLA4 and neoplasm.